医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ニュース
添付文書
薬の臨床実感＆助言集

BRUKINSA

BeiGene Receives Positive CHMP Opinion for BRUKINSA® (Zanubrutinib) for the Treatment of Adults with Waldenström’s Macroglobulinemia

BeiGene Receives Positive CHMP Opinion for BRUKINSA® (Zanubrutinib) for the Treatment of Adults with Waldenström’s Macroglobulinemia

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: BeiGene Receives Positive CHMP BRUKINSA for the Treatment of Adults with Waldenström’s Macroglobulinemia Opinion for zanubrutinib

2021年09月17日

$U.S. FDA Grants BRUKINSA® (Zanubrutinib) Accelerated Approval in Relapsed or Refractory Marginal Zone Lymphoma$

U.S. FDA Grants BRUKINSA® (Zanubrutinib) Accelerated Approval in Relapsed or Refractory Marginal Zone Lymphoma

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: Accelerated Approval in Relapsed or Refractory Marginal Zone Lymphoma BRUKINSA FDA Grants zanubrutinib

2021年09月15日

U.S. FDA Grants BRUKINSA® (Zanubrutinib) Approval in Waldenström’s Macroglobulinemia

U.S. FDA Grants BRUKINSA® (Zanubrutinib) Approval in Waldenström’s Macroglobulinemia

バイオテクノロジーヘルスケア製薬　 TimeLine: Approval in Waldenström’s Macroglobulinemia BRUKINSA FDA Grants zanubrutinib

2021年09月02日

BeiGene Announces First Presentation of the Phase 3 ALPINE Trial Comparing BRUKINSA® (Zanubrutinib) to Ibrutinib in Chronic Lymphocytic Leukemia to Be Featured in Presidential Symposium at EHA2021

BeiGene Announces First Presentation of the Phase 3 ALPINE Trial Comparing BRUKINSA® (Zanubrutinib) to Ibrutinib in Chronic Lymphocytic Leukemia to Be Featured in Presidential Symposium at EHA2021

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: ALPINE Trial Comparing BRUKINSA zanubrutinib

2021年06月01日

BeiGene Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for BRUKINSA® (Zanubrutinib) in Marginal Zone Lymphoma

BeiGene Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for BRUKINSA® (Zanubrutinib) in Marginal Zone Lymphoma

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: BeiGene Announces BRUKINSA FDA Acceptance and Priority Review in Marginal Zone Lymphoma zanubrutinib

2021年05月19日

BRUKINSA® (Zanubrutinib) Demonstrates Superior Objective Response Rate by Investigator Assessment and Reduced Rates of Atrial Fibrillation or Flutter at Interim Analysis in Head-to-Head Trial Against Ibrutinib in Chronic Lymphocytic Leukemia

BRUKINSA® (Zanubrutinib) Demonstrates Superior Objective Response Rate by Investigator Assessment and Reduced Rates of Atrial Fibrillation or Flutter at Interim Analysis in Head-to-Head Trial Against Ibrutinib in Chronic Lymphocytic Leukemia

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: BRUKINSA Demonstrates Superior Objective Response Rate by Investigator Assessment and Reduced Rates of Atrial Fibrillation or Flutter at Interim Analysis in Head-to-Head Trial Against Ibrutinib in Chronic Lymp zanubrutinib

2021年04月28日

BeiGene Announces Acceptance and Priority Review by Health Canada of New Drug Submission for BRUKINSA® (zanubrutinib) in Waldenström’s Macroglobulinemia

BeiGene Announces Acceptance and Priority Review by Health Canada of New Drug Submission for BRUKINSA® (zanubrutinib) in Waldenström’s Macroglobulinemia

その他ヘルスバイオテクノロジーヘルスケアヘルス一般外科心臓学腫瘍学臨床試験製薬　 TimeLine: BeiGene Announces Acceptance and Priority Review BRUKINSA in Waldenström’s Macroglobulinemia zanubrutinib

2020年09月09日